1[1]Silvestris F, Romito A, Fanelli P, et al. Long- term therapy with recombinant human erythropoietin (rHu - EPO) in progressing multiple myeloma. Ann Hematol, 1995; 70(6):313～318.
2[2]de Campos E, Radford J, Steward W, et al. Clinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small - cell lung cancer. J Clin Oncol, 1995; 13(7):1623～ 1631.
3[3]Hemy D, Abels R, Larholt K. Prediction of response to recombinant human erythropoietin (r- HuEPO/epoetin- α) therapy in cancer patients. Blood, 1995;85 (6): 1676～ 1678.
5[5]Rose EH,Abels RI,Nelson RA,et al.The use of rHuEPO in the treatment of anaemia related to myelodysplasia (MDS). Br. J Haematol, 1995,89(4) :831 ～ 837.
6[6]Shrivastava D, Rao TK,Sinert R, et al. The efficacy of erythropoietin in human immuno - deficiency virus - infected end - stage renal disease patients treated by maintenance hemodialysis. Am J Kidney Dis, 1995,25(6):904～906.
7[7]Flecknoe - Brown SC, Ross PJ, Fox JS. Optimising collection of autol -ogous blood: a pilot study of the use of recombinant human erythropoietin and pareteral iron. Med J Aust, 1995,61(1) :74～ 77.
8[8]Biesma D,Marx J,Kraaijenhangen R,et al. Lower homologous blood requirement in autologous blood donors after treatment with recombinant human erythropoietin. Lancet, 1994, 344:367 ～ 370.
9[9]Steegmann J, Lopez J, Otero M, et al. Erythropoietin treatment in al logeneic BMT accelerates erythroid reconstitution: result of a prospective controlled randomized trial. Bone Marrow Transplant, 1999; 10:541 ～ 546.
10[10]Revicki DA, Brown RE,Feeny DH,et al. Health - related quality of life associated with recombinant human erythropoietintherapy for predialysis chronic renal disease patients. Am. J Kidney Dis, 1995;25 (4):548 ～ 554.
